| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound, which has formulapresented below, or a pharmaceutically acceptable salt thereof. This compound can inhibit fibroblast growth factor receptor (FGFR) kinases in tumour tissues. In formula (I) A means a heteroaryl specified in indole, azaindole, benzofuran, benzothiophene, benzorhiazole, quinoline and pyrrole, or a benzene ring; Rparticularly means hydrogen, hydroxy, halogen, cyano, Chaloalkyl, Calkyl, Calkinyl; Rparticularly means hydrogen, hydroxy, halogen, cyano, Chaloalkyl, Calkyl, Calkinyl, Ccycloalkyl, phenylCalkyl, or Rand Rtogether with a nitrogen atom connected thereto form a 5-6-merous heterocyclyl group containing two oxygen atoms optionally substituted by a halogen; Rmeans H, Calkyl group, phenylCalkyl group or Chaloalkyl group; and Rmeans H or halogen.EFFECT: invention refers to a pharmaceutical composition and an agent for FGFR inhibition, an agent for preventing or treating a malignant new growth, a method for preventing or treating malignant new growths, and the use of the compounds for producing a medicinal agent for preventing or treating malignant new growths.10 cl, 35 tbl, 246 ex |
